In April 2020, INOVIO initiated and dosed first volunteer in a phase I trial to evaluate the safety, tolerability and immunological profile of INO 4800 administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRA® 2000 device in healthy adult volunteers (NCT04336410; COVID19-001). The open-label trial, later in April 2020, completed enrolment of 40 volunteers in the US    .
In April 2020, INOVIO announced that the US FDA has accepted the Investigational New Drug (IND) application for INO 4800 for the prevention of COVID-19 infection  .
As of April 2020, Inovio is evaluating INO 4800 in many challenge studies in multiple animal models. The company also reported that they intend to deliver INO 4800 for additional studies and emergency use  .
In preclinical studies, IN0 4800 demonstrated robust neutralizing antibody and T cell immune responses against coronavirus SARS-CoV-2 in mice and guinea pigs 
Administration of INO 4800, generated immune response in animal models. The preclinical studies were initiated in January 2020 and is ongoing  .
In April 2020, Coalition for Epidemic Preparedness Innovations (CEPI) granted $US6.9 million funding to Inovio to support a phase I/II trial of INO 4800 for COVID-2019 infections in South Korea  .
In March 2020, Inovio received $US5 million grant from the the Bill & Melinda Gates Foundation to accelerate the testing and scale up of CELLECTRA® 3PSP proprietary smart device for the intradermal delivery of INO 800, for the prevention of COVID-2019 infections  .
In February 2020, Twist Bioscience completed an offering of approximately 2.24 million shares of its common stock at an average price of approximately $US22.32 per share, raising approximately $US48.2 million in net proceeds  .
In January 2020, Coalition for Epidemic Preparedness Innovations (CEPI) awarded a grant of $US9 million to Inovio, to support preclinical and clinical development of INO 4800 for COVID-2019 infections  .